An "export-only" exception to pharmaceutical patents in Europe: Should the U.S. follow suit?
Research output: Contribution to journal › Journal article › Research › peer-review
Timo Minssen, Aaron Kesselheim, Jonathan Darrow
A new European Union policy could increase the supply of legitimate pharmaceuticals in developing countries and thereby minimize the problem of counterfeit medicines, but many challenges remain. This paper describes the proposed European legislation and discusses its' potential strengths, weaknesses, opportunities and threats. Ultimately, we consider if the United States should consider similar policies.
|Publication status||Published - 3 Jan 2019|